Cash flows from operating activities: | |
Net loss | -20.41M |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Depreciation and amortization | |
Stock-based compensation expense | 2.44M |
Change in common stock warrant value | |
Amortization of debt issuance costs | |
Loss on sale of investments, property and equipment | |
Changes in operating assets and liabilities: | |
Prepaid expenses and other assets | 1.74M |
Accounts payable | -26K |
Accrued clinical and development expenses | |
Accrued liabilities | -2.16M |
Deferred rent | |
Net cash used in operating activities | |
Cash flows from investing activities: | |
Acquisition of property and equipment | 0 |
Acquisition of marketable securities | |
Proceeds from sales and maturities of marketable securities | |
Restricted cash | |
Net cash provided by (used in) investing activities | |
Cash flows from financing activities: | |
Proceeds from redeemable convertible preferred stock, net | |
Proceeds from issuance of common stock and warrants, net of offering expenses | 27K |
Deferred offering costs | |
Proceeds from issuance of notes payable | |
Repayment of notes payable | |
Net cash provided by financing activities | |
Net increase (decrease) in cash and cash equivalents | 5.57M |
Cash and cash equivalents, beginning of period | 9.59M |
Cash and cash equivalents, end of period | 15.16M |
Supplemental schedule of non-cash investing and financing activities | |
Deferred stock-based compensation | |
Cumulative effect of change in accounting principle - Reclassification of common stock warrants to liability upon adoption of ASC 815 | |
Change in unrealized gain (loss) on marketable securities | |
Conversion of redeemable preferred stock | |
Dividend related to beneficial conversion feature of redeemable convertible preferred stock. |